Patients on SGLT2 inhibitors (41.9% vs. 18.7%, p < 0.0005), those on DPP4 inhibitors (30.6 vs. 17.7%, p < 0.0005), sulfonylureas (32.1 vs. 16.9%, p = 0.0001) and insulin (44.7% vs. 11.0%, p < 0.0005), were more likely to have diabetes-related information in their DS, compared to those who were not taking any of the medications (p < 0.0005, for all comparison) during admission. Here, SLC5A2 is linked to diabetes mellitus.